![Jonathan Hepple](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jonathan Hepple
Directeur/Membre du Conseil chez
Nucleome Therapeutics Ltd.
Profil
Jonathan Hepple is currently a Non-Executive Director at MISSION Therapeutics Ltd., Carrick Therapeutics Ltd., Nucleome Therapeutics Ltd., Rosetta Capital Ltd., and Oxford Science Enterprises PLC.
He previously held positions as a Director at GlycoMimetics, Inc., ProCertus BioPharm, Inc., Aprea Therapeutics AB, NovImmune SA, Axelar AB, Covagen AG, Opsona Therapeutics Ltd., and Tranzyme Pharma, Inc. (Canada).
He was also a Director at ClanoTech AB from 2013 to 2020 and an Independent Director at Aprea Therapeutics, Inc. from 2015 to 2020.
Additionally, he worked as a Partner at Kernel Management Partners Ltd. Dr. Hepple obtained his undergraduate degree from the University of Oxford in 1992 and his doctorate degree from the University of Cambridge in 1997.
Postes actifs de Jonathan Hepple
| Sociétés | Poste | Début |
|---|---|---|
Rosetta Capital Ltd.
 Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital invests in early and mid-stage growth companies in biotechnology-related sectors. The firm invest in acquisition financing and spin-off transactions. | Private Equity Investor | 01/01/2001 |
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs targeting enzymes involved in cancer and other diseases | Directeur/Membre du Conseil | 24/03/2021 |
Nucleome Therapeutics Ltd.
 Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecular drugs for autoimmune diseases | Directeur/Membre du Conseil | 25/05/2021 |
Carrick Therapeutics Ltd.
 Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company for oncological therapy treatment | Directeur/Membre du Conseil | - |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million. | Consultant / Advisor | 01/07/2020 |
Anciens postes connus de Jonathan Hepple
| Sociétés | Poste | Fin |
|---|---|---|
| APREA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 16/09/2020 |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer and macular degeneration | Directeur/Membre du Conseil | 01/04/2020 |
Tranzyme Pharma, Inc. (Canada) | Directeur/Membre du Conseil | - |
GlycoMimetics, Inc.
 GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Directeur/Membre du Conseil | - |
| ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Jonathan Hepple
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
95
Relations au 1er degré
19
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 19 |
|---|---|
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlycoMimetics, Inc.
GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Health Technology |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital invests in early and mid-stage growth companies in biotechnology-related sectors. The firm invest in acquisition financing and spin-off transactions. | Finance |
Kernel Management Partners Ltd.
 Kernel Management Partners Ltd. Investment ManagersFinance Kernel Capital invests in companies located in Ireland. The firm focuses on sectors such as software & web communications, telecoms, networks, chip, sensors & engineering. It participates in seed and early stage capital transactions with an investment size of EUR 0.5 - 2 million and also acts as lead & Co-investor. | Finance |
ProCertus BioPharm, Inc.
 ProCertus BioPharm, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-based pharmaceutical company | Health Technology |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Novimmune SA
 Novimmune SA BiotechnologyHealth Technology Operates as a drug discovery and development company | Health Technology |
Axelar AB
 Axelar AB BiotechnologyHealth Technology Provides oral anti-cancer therapies | Health Technology |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Health Technology |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Provides immunology drug for treatment of inflammatory diseases | Health Technology |
Tranzyme Pharma, Inc. (Canada) | |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer and macular degeneration | Health Technology |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs targeting enzymes involved in cancer and other diseases | Health Technology |
Carrick Therapeutics Ltd.
Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company for oncological therapy treatment | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million. | Finance |
Aprea Therapeutics, Inc.
 Aprea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel anticancer compounds | Health Technology |
Nucleome Therapeutics Ltd.
Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecular drugs for autoimmune diseases | Health Technology |
Choisissez Zonebourse 
